somnomed is a recession proof stock as stated by management. --------------
SomnoMed Limited does not expect at this point in time that the Global Financial Crisis will impact significantly on its business, as the sleep disorder treatment markets are at a very early stage in their development and the need for treatment of obstructive sleep apnea is growing constantly disregarding of the economic circumstances.
Demand for the SomnoDent MAS device is primarily driven by the growing number of patients diagnosed with obstructive sleep apnea, the significant number of patients who cannot tolerate or do not wish to use a CPAP mask and the growing support from sleep specialists around the world to use dental sleep devices as treatment for sleep apnea.
SOM Price at posting:
40.0¢ Sentiment: LT Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)